Wells Fargo & Company Enlivex Therapeutics Ltd. Put Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
23Shares Held
324KCall Options Held
22.8KPut Options Held
29.1K-
Morgan Stanley New York, NY72.1KShares$95,1980.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny69.9KShares$92,2530.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA67.9KShares$89,6840.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il55.5KShares$73,2930.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$19,8000.09% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $24.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...